Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC

Area of Science:

• Oncology
• Molecular Biology
• Cancer Signaling Pathways

Background:

• The PI3K/AKT/mTOR pathway is crucial for cell growth and proliferation.
• Dysregulation of this pathway is common in cancer, particularly non-small cell lung cancer (NSCLC).
• Activated PI3K/AKT/mTOR signaling in NSCLC is linked to aggressive disease and poor patient prognosis.

Purpose of the Study:

• To explore strategies for overcoming resistance to PI3K/AKT/mTOR pathway inhibitors in NSCLC.
• To investigate the potential of co-targeting resistance mediators alongside PI3K pathway inhibition.
• To assess the role of PI3K pathway inhibition in overcoming radioresistance, chemoresistance, and immune evasion in NSCLC.

Main Methods:

• Review of existing research on PI3K/AKT/mTOR pathway dysregulation in NSCLC.
• Analysis of mechanisms contributing to innate and acquired resistance to PI3K inhibitors.
• Exploration of potential co-targeting strategies involving cell surface receptors and intracellular signaling pathways.
• Evaluation of PI3K pathway's role in radioresistance, chemoresistance, and immune evasion.

Main Results:

• Activation of the PI3K/AKT/mTOR pathway in NSCLC promotes aggressive disease and poor prognosis.
• Significant challenges exist due to innate and acquired resistance to PI3K inhibitors.
• Co-targeting resistance mechanisms, such as related receptors or cross-talking pathways, may enhance treatment efficacy.
• PI3K pathway inhibition holds potential to overcome radioresistance, chemoresistance, and immune evasion in NSCLC.

Conclusions:

• Targeted inhibition of the PI3K/AKT/mTOR pathway is a key area of investigation for NSCLC treatment.
• Overcoming resistance is critical for the success of PI3K inhibitors in NSCLC.
• Co-targeting strategies and identifying suitable patient cohorts are essential for advancing PI3K-targeted therapies in NSCLC.